Company News - Yuanshan Group (00551.HK) reported a cumulative operating income of approximately $6.017 billion for the first nine months, a decrease of 1% year-on-year [2] - Baoshan International (03813.HK) recorded a cumulative operating income of 12.903 billion yuan for the first nine months, down 7.7% year-on-year [2] - Longyuan Power (00916.HK) achieved a cumulative power generation of 56,546,706 MWh in the first nine months, a decline of 0.53% year-on-year; excluding the impact of thermal power, there was a year-on-year increase of 13.81%, with wind power up 5.30% and solar power up 77.98% [2] Financial Performance - Qinhuangdao Port Co., Ltd. (03369.HK) reported a total throughput of 317 million tons for the first nine months, an increase of 5.56% year-on-year [3] - New China Life Insurance (01336.HK) expects net profit attributable to shareholders for the first three quarters to be between 29.986 billion yuan and 34.122 billion yuan, representing a year-on-year growth of 45% to 65% [3] - Jiangshan Holdings (00295.HK) reported a total power generation of approximately 238,787 MWh for the first nine months, a decrease of 4.83% year-on-year [3] - Morning News Technology (02000.HK) reported an unaudited revenue of 270 million HKD for the first nine months, down 7.6% year-on-year [3] - Dekang Agriculture and Animal Husbandry (02419.HK) sold approximately 7.5509 million pigs in the first nine months, with sales revenue of approximately 14.277 billion yuan [3] Drug Approvals and Developments - Hengrui Medicine (01276.HK) received a clinical trial approval notice for SHR-A2102, a targeted Nectin-4 antibody-drug conjugate (ADC) developed in-house; global sales for similar products are expected to reach approximately $1.949 billion in 2024 according to EvaluatePharma [3] - Hutchison China MediTech (00013.HK) plans to announce FRUSICA-2 registration study data at the 2025 European Society for Medical Oncology annual meeting [3] - CSPC Pharmaceutical Group (01093.HK) had its new drug application for Idaglutide α injection accepted by the National Medical Products Administration [3] Corporate Actions - Huazhen Medical (01931.HK) announced the acquisition of U.S. properties and the establishment of a U.S. subsidiary, ETHK BANK, to promote stablecoins and intellectual property securitization in the U.S. [3] - Lihigh Holdings (08472.HK) plans to invest 24 million HKD in cryptocurrency and commodities [3] - Hisense Home Appliances (00921.HK) and its subsidiaries subscribed to a financial product from Jingu Trust worth 1.739 billion HKD [3] Real Estate Performance - New Town Development (01030.HK) reported cumulative contract sales of 15.050 billion yuan for the first nine months, a decrease of 52.72% year-on-year [3] - Longfor Group (00960.HK) achieved total contract sales of 50.75 billion yuan in the first nine months [3] - CIFI Holdings Group (00884.HK) reported cumulative contract sales of approximately 13.06 billion yuan for the first nine months [3] - Ronshine China Holdings (03301.HK) reported contract sales of 3 billion yuan for the first nine months, down 45.3% year-on-year [3] - Yuzhou Group (01628.HK) reported cumulative sales of 4.913 billion yuan for the first nine months [3] - Yida China (03639.HK) reported contract sales of approximately 572 million yuan for the first nine months, down 24.74% year-on-year [3] Financing and Buyback Activities - Geely Automobile (00175.HK) was approved to issue debt financing instruments totaling no more than 10 billion yuan [3] - HSBC Holdings (00005.HK) repurchased 1.58 million HKD worth of shares at prices ranging from 102.2 to 103.77 HKD [3] - Xiaomi Group-W (01810.HK) repurchased 400 million HKD worth of shares at prices ranging from 47.82 to 50.55 HKD [3] - Shoucheng Holdings (00697.HK) repurchased 890 million HKD worth of shares at prices ranging from 2.21 to 2.27 HKD [3]

Core Viewpoint - Baoshan International (03813.HK) announced that it will hold a board meeting on November 12, 2025, primarily to approve and publish the unaudited consolidated results for the nine months ending September 30, 2025 [1] Summary by Category - Company Announcement - The board meeting is scheduled for November 12, 2025 [1] - The purpose of the meeting is to approve and publish the unaudited consolidated results for the nine months ending September 30, 2025 [1]

公司截至2025年9月30日止9个月的综合累计经营收益净额：129.03亿元(2024年：139.83亿元)，与去年 同期相比下跌7.7%。 宝胜国际(03813)发布公告，于2025年9月，公司本月综合经营收益净额(即相当于总销售额减销售折扣及 销售退货)：13.48亿元(人民币，单位下同)(2024年：14.17亿元，与去年同月相比下跌4.8%。 ...

Core Insights - The company reported a net operating revenue of RMB 1.348 billion for September 2025, representing a decline of 4.8% compared to the same month last year [1] - For the nine months ending September 30, 2025, the cumulative net operating revenue was RMB 12.903 billion, down 7.7% year-on-year [1] Financial Performance - September 2025 net operating revenue: RMB 1.348 billion, down 4.8% year-on-year [1] - Cumulative net operating revenue for the first nine months of 2025: RMB 12.903 billion, down 7.7% compared to the same period last year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 POU SHENG INTERNATIONAL (HOLDINGS) LIMITED 寶勝國際（ 控 股 ）有 限公司 （於百慕達註冊成立之有限公司） （股份代號：3813） 董事會會議召開日期 寶勝國際（控股）有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二 零二五年十一月十二日（星期三）舉行董事會會議，其目的主要是批准及刊發本公 司及其子公司截至二零二五年九月三十日止九個月之未經審核綜合業績。 承董事會命 主席 邱暉堯 香港，二零二五年十月十三日 於本公告日期，董事會成員包括： 非執行董事 邱暉堯先生（主席）、蔡佩君女士及李義男先生 執行董事 胡嘉和先生、張舒卿女士（首席執行官）及陳立傑先生（首席財務官） 獨立非執行董事 陳煥鐘先生、馮雷明先生及劉詩亮先生 網址：www.pousheng.com ...

POU SHENG INTERNATIONAL (HOLDINGS) LIMITED 寶勝國際（ 控 股 ）有 限公司 （於百慕達註冊成立之有限公司） （股份代號：3813） 二零二五年九月之每月收益公告 本公司為聯交所主板上市公司裕元的子公司。按照國際財務報告準則，裕元被 視為臺灣證交所上市公司寶成工業之子公司。寶成工業根據臺灣證券交易所的 規例規定刊發每月收益公告。 由於裕元於今日公佈其若干綜合財務資料，故本公司根據上市規則第13.09(2)條 及證券及期貨條例第XIVA部刊發本公告，確保及時向投資者提供最新資料。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 月份：二零二五年九月 邱暉堯先生（主席）、蔡佩君女士及李義男先生 承董事會命 主席 邱暉堯 香港，二零二五年十月十三日 於本公告日期，董事會成員包括： 非執行董事 寶勝國際（控股）有限公司（「本公司」）為香港聯合交易所有限公司（「聯交所」）主 板上市公司裕元工業（集團）有限公司（「裕元」 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 寶勝國際(控股)有限公司 呈交日期: 2025年10月3日 第 2 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03813 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HK ...

Major Events - The clinical trial for the combination treatment of Tienogtinin and Furvestrant for HR-positive/HER2-negative or low-expressing recurrent or metastatic breast cancer has been approved for Phase II [1] - Feiyang Group's subsidiary signed a strategic cooperation framework agreement with Qingdao Cultural Property Exchange Center for potential collaboration in the digitalization of cultural tourism assets [1] - Kaizhile International entered the TCG sector by reaching an operational service cooperation with the globally renowned IP Pokémon [1] - CIMC Group's BWO plans to lease two lifting living platforms, "Huaye Long" and "Huashang Long," to Hailong 16 and Hailong 17 companies [1] - Goldwind Technology intends to invest 18.92 billion in building a wind-hydrogen-ammonia integrated project in Inner Mongolia [1] Financial Data - Zhongyuan Jianye reported a contract sales of 7.28 billion for the first eight months, a year-on-year decrease of 20.0% [1] - Jianye Real Estate's total property contract sales for the first eight months reached 5.62 billion, down 5.0% year-on-year [1] - Baoshen International's cumulative operating income net for the first eight months was approximately 11.555 billion, a decline of 8.1% year-on-year [1] - China Resources Power's subsidiary power plants sold a total of 144 million megawatt-hours in the first eight months, an increase of 5.9% year-on-year [1] - Jiangshan Holdings reported a total solar power generation of approximately 218.2 thousand megawatt-hours in the first eight months, a decrease of 3.55% year-on-year [1]

Group 1 - The company reported a net operating income of approximately 1.241 billion for September 2025, representing a year-on-year decline of 6.0% [1] - The cumulative net operating income for the first eight months was approximately 11.555 billion, showing a year-on-year decrease of 8.1% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 POU SHENG INTERNATIONAL (HOLDINGS) LIMITED 寶勝國際（ 控 股 ）有 限公司 （於百慕達註冊成立之有限公司） （股份代號：3813） 二零二五年八月之每月收益公告 本公司為聯交所主板上市公司裕元的子公司。按照國際財務報告準則，裕元被 視為臺灣證交所上市公司寶成工業之子公司。寶成工業根據臺灣證券交易所的 規例規定刊發每月收益公告。 由於裕元於今日公佈其若干綜合財務資料，故本公司根據上市規則第13.09(2)條 及證券及期貨條例第XIVA部刊發本公告，確保及時向投資者提供最新資料。 寶勝國際（控股）有限公司（「本公司」）為香港聯合交易所有限公司（「聯交所」）主 板上市公司裕元工業（集團）有限公司（「裕元」）的子公司。按照國際財務報告準則， 裕元被視為臺灣證券交易所股份有限公司（「臺灣證交所」）上市公司寶成工業股份 有限公司（「寶成工業」）之子公司。根據臺灣證券交易所 ...